News Releases

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 3, 2019-- LabCorp® (NYSE: LH) announced today the pricing terms of its previously announced cash tender offer (the Offer) for up to $300,000,000 principal amount (the Tender Cap) of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 3, 2019-- LabCorp® (NYSE: LH) announced today the early results of its previously announced cash tender offer (the Offer) for up to $300,000,000 principal amount (the Tender Cap) of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior

Current CFO of Qurate Retail Group and Former CFO of J. C. Penney Brings More Than 30 Years of Finance Experience Across Multiple Industries BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 26, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 19, 2019-- LabCorp (NYSE: LH) announced today that it has provided notice of its intention to redeem all of its outstanding Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) for cash on Dec.

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2019-- LabCorp® (NYSE: LH) announced today that it has priced its offering of $1,050,000,000 in senior notes. The offering consists of two tranches: $400,000,000 aggregate principal amount of 2.300% Senior Notes due 2024 (the 2024 Notes) and $650,000,000

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2019-- LabCorp® (NYSE: LH) announced today that it has commenced a cash tender offer (the Offer) to purchase up to $300,000,000 principal amount (the Tender Cap) of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior Notes due 2020

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2019-- LabCorp® (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches (the Notes). The Notes will be senior unsecured obligations and will rank equally with

John Ratliff is departing the company to pursue another opportunity Dr. Brian Caveney has been named executive vice president and president of Diagnostics Mark Schroeder has been named executive vice president and president of Diagnostics laboratory operations and global supply chain These new

Q3 revenue of $2.9 billion , up 3.4% over $2.8 billion last year Q3 diluted EPS of $2.25 , down from $3.10 last year, which included the net gain on the disposition of the Food Solutions business of $1.22 per share Q3 adjusted EPS of $2.90 , up 5.8% over $2.74 last year Q3 free cash flow of $363

 South Bend Medical Foundation and LabCorp Also Establish Pathology Services Collaboration to Serve Customers and Patients Across Four States BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient

Agreement Establishes Database and Information Exchange Platform to Facilitate Care-Delivery Collaboration Between Participating New Jersey FQHCs Through LabCorp’s Care Intelligence Module BURLINGTON, N.C. & EDISON, N.J. & HAMILTON, N.J. --(BUSINESS WIRE)--Oct.

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 15, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it will mark its 50th anniversary at a celebration Oct. 15 in Burlington, North Carolina , where the company has

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 14, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

    John Ratliff , current CEO of Covance, to become CEO of LabCorp Diagnostics   Dr. Paul Kirchgraber , current senior vice president and head of Covance’s clinical trial testing solutions, to become CEO of Covance   Both business segment CEO roles are effective Nov. 1 when Adam H.

Study of nearly 30,000 cases finds that non-invasive cfDNA screening for fetal aneuploidy in pregnancies with twins, triplets, and higher-order multiples meets or exceeds performance of singleton pregnancy screening   BURLINGTON, N.C. --(BUSINESS WIRE)--Sep.

  BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 24, 2019-- LabCorp® (NYSE: LH) will release its third quarter of 2019 financial results before the market opens on Thursday, Oct. 24, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash

Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care,

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 29, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Monday, Sept. 9, 2019 at 9:55 a.m. ET . A live audio webcast will be available via the Company

Program Expands the Company’s Growing and Unique FSPx Capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 29, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business has launched a laboratory solution within its functional

Q2 revenue of $2.88 billion , up 0.5% from $2.87 billion last year; excluding the disposition of businesses revenue grew 2.4% Q2 diluted EPS of $1.93 , down 15% from $2.27 last year; Q2 adjusted EPS of $2.93 , down 2% from $2.98 last year 2019 adjusted EPS guidance of $11.10 to $11.40 , up 1% to 3%

Pixel by LabCorp Now Available with Phlebotomy Collection Through LabCorp’s Nationwide Patient Service Center Network BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced a significant expansion to its Pixel by LabCorp™

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 25, 2019-- LabCorp® (NYSE: LH) will release its second quarter of 2019 financial results before the market opens on Thursday, July 25, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

Philips IntelliSite Pathology Solution will be deployed across the Mount Sinai Health System to support greater efficiency and help improve patient care BURLINGTON, N.C. & NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Jun. 18, 2019-- LabCorp® (NYSE: LH) and the Mount Sinai Health System today announced